Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 72

Results For "strategy"

719 News Found

Merck brings new renewable energy to the grid through VPPA with Enel Green Power
News | March 18, 2021

Merck brings new renewable energy to the grid through VPPA with Enel Green Power

Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power


Vivimed Labs receives products approvals from Uzbekistan
News | March 09, 2021

Vivimed Labs receives products approvals from Uzbekistan

Vivimed strategy is to increase its share of Branded products in CIS Markets.


Aarti Speciality Chemicals receives PLI approval for pharmaceutical sector
News | March 08, 2021

Aarti Speciality Chemicals receives PLI approval for pharmaceutical sector

The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.


Pharma sector will be $130 billion strong by 2030: EY-FICCI paper
News | March 04, 2021

Pharma sector will be $130 billion strong by 2030: EY-FICCI paper

The Indian pharma industry has grown at a compounded growth rate of ~11% in the domestic market and ~16% in exports over the last two decades


Merck FY20 sales up 8.6% euro 17.5 bn
News | March 04, 2021

Merck FY20 sales up 8.6% euro 17.5 bn

Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.


Accelerated growth in pharma depends on the right policies: Experts
News | March 01, 2021

Accelerated growth in pharma depends on the right policies: Experts

A mix of favorable government policies and a positive environment will create a win-win situation for all stakeholders


2021 will be a game-changer for pharma industry, says experts
News | February 13, 2021

2021 will be a game-changer for pharma industry, says experts

The pandemic has provided tailwinds in terms of access to rural healthcare and India’s emergence as a vaccine powerhouse


Zydus Cadila awaits product approvals worth US $6 billion
News | January 21, 2021

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business


Bayer gearing up for 2021-2030 decade
News | January 16, 2021

Bayer gearing up for 2021-2030 decade

Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business